18 terminated. 18 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Terminated 18 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study Aramchol, Placebo, Ultrasound - Gallstones | Phase 2 | Terminated | Galmed Pharmaceuticals Ltd | 10 | 2014-10-01 | 2015-10-05 |
| Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Gemcitabine-Pazopanib - Cholangiocarcinoma, Gallbladder Carcinoma | Phase 2 | Terminated | Hellenic Cooperative Oncology Group | 29 | 2013-06-28 | 2018-11-07 |
| Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin - Cholangiocarcinoma, Hepatobiliary Neoplasm | Phase 2 | Terminated | Stanford University | 2 | 2011-01-01 | 2016-07-29 |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers cediranib maleate, oxaliplatin, leucovorin calcium - Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2010-10-01 | 2017-03-29 |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer palonosetron hydrochloride, placebo - Anal Cancer, Carcinoma of the Appendix | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 7 | 2009-09-01 | 2017-11-24 |
| A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer Gemcitabine, Oxaliplatin, Sorafenib - Cholangiocarcinoma, Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Miami | 9 | 2009-08-01 | 2018-01-03 |
| Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Cisplatin, Erlotinib, Gemcitabine - Hepatocellular Carcinoma, Cholangiocellular Carcinoma | Phase 2 | Terminated | New Mexico Cancer Research Alliance | 33 | 2007-08-01 | 2018-06-29 |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery trastuzumab, laboratory biomarker analysis - Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2007-05-01 | 2019-08-20 |
| Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo AMT2003 - Gastrointestinal Cancer, Prostate Cancer | Phase 2 / Phase 3 | Terminated | Auron Healthcare GmbH | 67 | 2006-05-01 | 2013-03-20 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder bortezomib - Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2004-01-01 | 2017-07-02 |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim - Colorectal Cancer, Esophageal Cancer | Phase 2 | Terminated | The University of Texas Medical Branch, Galveston | 7 | 2002-07-01 | 2013-05-16 |
| Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) IL-10 - Bile Duct Diseases, Biliary Tract Diseases | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 316 | 2002-01-01 | 2015-11-02 |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer ixabepilone, laboratory biomarker analysis - Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2001-08-01 | 2014-05-14 |
| Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer becatecarin - Extrahepatic Bile Duct Cancer, Gallbladder Cancer | Phase 2 | Terminated | Case Comprehensive Cancer Center | 72 | 1999-04-01 | 2010-06-11 |
Gallbladder Neoplasms (16) · Bile Duct Neoplasms (10) · Cholangiocarcinoma (8) · Carcinoma, Hepatocellular (6) · Liver Neoplasms (4) · Pancreatic Neoplasms (4) · Biliary Tract Neoplasms (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Esophageal Neoplasms (3) · Stomach Neoplasms (3) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2)
Digestive System Diseases (18) · Biliary Tract Diseases (17) · Digestive System Neoplasms (16) · Neoplasms by Site (16) · Neoplasms (15) · Adenocarcinoma (13) · Biliary Tract Neoplasms (13) · Carcinoma (13) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (13) · Bile Duct Diseases (10) · Liver Diseases (8) · Gastrointestinal Diseases (5) · Colonic Diseases (4)
Gemcitabine (6) · Cisplatin (4) · Fluorouracil (3) · Leucovorin (2) · Oxaliplatin (2) · Bortezomib (1) · Capecitabine (1) · Carboplatin (1) · Erlotinib Hydrochloride (1) · Interleukin-10 (1) · Liver Transplantation (1) · Palonosetron (1) · Radiosurgery (1) · Sorafenib (1) · Trastuzumab (1)
National Cancer Institute (NCI) (4) · Alliance for Clinical Trials in Oncology (1) · Auron Healthcare GmbH (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Case Comprehensive Cancer Center (1) · EMD Serono Research & Development Institute, Inc. (1) · Elevation Oncology (1) · Galmed Pharmaceuticals Ltd (1) · Hellenic Cooperative Oncology Group (1) · Merck Sharp & Dohme LLC (1) · New Mexico Cancer Research Alliance (1) · Stanford University (1) · The University of Texas Medical Branch, Galveston (1) · University of Miami (1) · University of Michigan Rogel Cancer Center (1)
United States (13) · Australia (2) · China (2) · Germany (2) · South Korea (2) · Argentina (1) · Bosnia and Herzegovina (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Greece (1) · Israel (1) · Italy (1) · Japan (1)
Afshin Dowlati, MD (1) · Ahmed Kaseb (1) · Ari D Baron, MD (1) · Asnat Raziel, MD (1) · Daniel T Chang (1) · Hedy Kindler (1) · Joachim Drevs, PD Dr. Med (1) · Joseph Sgouros, MD (1) · Michele Yvette Halyard, MD (1) · Peter Hosein, MD (1) · Robert P. Whitehead, MD (1) · Smitha Krishnamurthi (1) · Steven Cohen (1) · Vaibhav Sahai, MBBS, MS (1)
PMID 19399502, PMID 24512954, PMID 32461347, PMID 38875119, PMID 41428976
2019 (1), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), P30CA014599 (1), P30CA043703 (1), U01CA062502 (1), U01CA063200 (1)